Mebias Discovery, Inc

MEBIAS holds a game-changing platform to discover next generation, GPCR drugs devoid of on-target side effects. G-protein Coupled Receptor (GPCR) therapeutics comprise ~30% of current prescribed drugs. Mebias’ understanding of protein dynamics of GPCRs offers a unique advantage. Given our experience and access to two key technologies – native GPCR purification and protein nuclear magnetic resonance – our approach offers resolution to identify agonists that is lacking in other methodologies. We have delivered a series of biased mu opioid receptor scaffolds among which is an clinical stage compound. The Mebias platform significantly decreases the time and costs to deliver optimized leads. Our initial areas of focus are CNS/Pain, OUD, Metabolic, and Inflammatory related disorders. Expertise / Assets • Rapid identification and optimization of IND candidates devoid of on-target adverse effects, enabled by a fully validated assay suite which identifies ligand-induced dynamic conformation of GPCR signaling. • Differentiated mu-opioid receptor agonist (MEB-1170) for the treatment of OUD and pain (lacking respiratory depression/GI motility issues/tolerance and does not demonstrate potential for abuse liability) Business Proposal • Seeking co-development and/or license our mu-opioid drug candidates • Research funding/collaboration for lead discovery of additional targets in selected disease areas